{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:40:07Z","timestamp":1780684807716,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.genhosppsych.2025.07.001","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:24:35Z","timestamp":1751581475000},"page":"116-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Should we skip the trip? Clinical implications of psychedelic-associated subjective effects and the potential role of non-hallucinogenic alternatives"],"prefix":"10.1016","volume":"96","author":[{"given":"Kush V.","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Asuncion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Zisook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0005","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2147\/DDDT.S443177","article-title":"The promise of therapeutic psilocybin: an evaluation of the 134 clinical trials, 54 potential indications, and 0 marketing approvals on ClinicalTrials.gov","volume":"18","author":"Norring","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/2050324520974484","article-title":"2019: a year of expansion in psychedelic research, industry, and deregulation","volume":"6","author":"Aday","year":"2020","journal-title":"Drug Sci Policy Law"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.07.001_bb0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/psymed.2023.0013","article-title":"Psychedelic commercialization: a wide-spanning overview of the emerging psychedelic industry","volume":"1","author":"Aday","year":"2023","journal-title":"Psyched Med"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.07.001_bb0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/02698811231158891","article-title":"Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions","volume":"37","author":"Cooper","year":"2023","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109610","article-title":"Psychedelics: threshold of a therapeutic revolution","volume":"236","author":"Heal","year":"2023","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.07.001_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1176\/appi.ajp.20230902","article-title":"Psychedelics for the treatment of psychiatric disorders: interpreting and translating available evidence and guidance for future research","volume":"182","author":"McIntyre","year":"2025","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.genhosppsych.2025.07.001_bb0035","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11920-022-01363-y","article-title":"The emerging field of psychedelic psychotherapy","volume":"24","author":"Barber","year":"2022","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.866018","article-title":"Models of psychedelic-assisted psychotherapy: a contemporary assessment and an introduction to EMBARK, a transdiagnostic, trans-drug model","volume":"13","author":"Brennan","year":"2022","journal-title":"Front Psychol"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0045","doi-asserted-by":"crossref","DOI":"10.1177\/00221678221085800","article-title":"Integration in psychedelic-assisted treatments: recurring themes in current providers\u2019 definitions, challenges, and concerns","author":"Earleywine","year":"2022","journal-title":"J Human Psychol"},{"issue":"8","key":"10.1016\/j.genhosppsych.2025.07.001_bb0050","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00213-024-06620-x","article-title":"Psychedelic-assisted psychotherapy: where is the psychotherapy research?","volume":"241","author":"Aday","year":"2024","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.07.001_bb0055","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects","volume":"4","author":"Olson","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s44159-024-00345-6","article-title":"Clinically relevant acute subjective effects of psychedelics beyond mystical experience","author":"Yaden","year":"2024","journal-title":"Nat Rev Psychol"},{"issue":"4","key":"10.1016\/j.genhosppsych.2025.07.001_bb0065","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/0269881121992676","article-title":"Dose\u2013response relationships of psilocybin-induced subjective experiences in humans","volume":"35","author":"Hirschfeld","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"11","key":"10.1016\/j.genhosppsych.2025.07.001_bb0070","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41386-023-01588-2","article-title":"Dose-response relationships of LSD-induced subjective experiences in humans","volume":"48","author":"Hirschfeld","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.genhosppsych.2025.07.001_bb0075","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40262-017-0513-9","article-title":"Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects","volume":"56","author":"Dolder","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.genhosppsych.2025.07.001_bb0080","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cpt.2821","article-title":"Pharmacokinetics and pharmacodynamics of Oral Psilocybin Administration in Healthy Participants","volume":"113","author":"Holze","year":"2023","journal-title":"Clin Pharmacol Therap"},{"issue":"11","key":"10.1016\/j.genhosppsych.2025.07.001_bb0085","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.07.001_bb0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/02698811231200019","article-title":"Assessment of the acute subjective psychedelic experience: a review of patient-reported outcome measures in clinical research on classical psychedelics","volume":"38","author":"Hovmand","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"8","key":"10.1016\/j.genhosppsych.2025.07.001_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV)","volume":"5","author":"Studerus","year":"2010","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.genhosppsych.2025.07.001_bb0100","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J Psychopharmacol"},{"issue":"12","key":"10.1016\/j.genhosppsych.2025.07.001_bb0105","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"9","key":"10.1016\/j.genhosppsych.2025.07.001_bb0110","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jad.2024.12.061","article-title":"The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression","volume":"372","author":"Goodwin","year":"2025","journal-title":"J Affect Disord"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.07.001_bb0120","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.07.001_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/s44184-023-00053-8","article-title":"The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects","volume":"3","author":"Bhatt","year":"2024","journal-title":"Npj Ment Health Res"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102799","article-title":"Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial","volume":"76","author":"Erritzoe","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.07.001_bb0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"8","key":"10.1016\/j.genhosppsych.2025.07.001_bb0140","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/02698811221084063","article-title":"Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms","volume":"36","author":"Kopra","year":"2022","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0145","article-title":"Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports","volume":"1\u201313","author":"Yildirim","year":"2024","journal-title":"Psychol Med"},{"issue":"10","key":"10.1016\/j.genhosppsych.2025.07.001_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293349","article-title":"Extended difficulties following the use of psychedelic drugs: a mixed methods study","volume":"18","author":"Evans","year":"2023","journal-title":"PloS One"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0155","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2024.2546","article-title":"Adverse events in studies of classic psychedelics: a systematic review and Meta-analysis","author":"Hinkle","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.07.001_bb0160","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/02698811211069100","article-title":"Adverse effects of psychedelics: from anecdotes and misinformation to systematic science","volume":"36","author":"Schlag","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.07.001_bb0165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1176\/appi.ajp.20230665","article-title":"Psychotherapy in psychedelic treatment: safe, evidence-based, and necessary","volume":"181","author":"Alpert","year":"2024","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.07.001_bb0170","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0175","series-title":"Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review","author":"Estric","year":"2025"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0180","article-title":"The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Psych"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0185","doi-asserted-by":"crossref","first-page":"1293243","DOI":"10.3389\/fpsyt.2023.1293243","article-title":"Group psychedelic therapy: empirical estimates of cost-savings and improved access","volume":"14","author":"Marseille","year":"2023","journal-title":"Front Psych"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.07.001_bb0190","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/psymed.2023.0060","article-title":"Patients\u2019 experiences discussing psychedelics for therapeutic purposes with physicians and other health care providers","volume":"2","author":"Pierre","year":"2024","journal-title":"Psyched Med"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.07.001_bb0195","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s11845-021-02668-2","article-title":"Psychedelic perceptions: mental health service user attitudes to psilocybin therapy","volume":"191","author":"Corrigan","year":"2022","journal-title":"Irish J Med Sci (1971)"},{"issue":"9","key":"10.1016\/j.genhosppsych.2025.07.001_bb0200","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/0269881120936508","article-title":"Perceived harm, motivations for use and subjective experiences of recreational psychedelic \u2018magic\u2019 mushroom use","volume":"34","author":"Roberts","year":"2020","journal-title":"J Psychopharmacol"},{"issue":"5","key":"10.1016\/j.genhosppsych.2025.07.001_bb0205","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","article-title":"Studying harms is key to improving psychedelic-assisted therapy\u2014participants call for changes to research landscape","volume":"80","author":"McNamee","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.07.001_bb0210","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41583-024-00876-0","article-title":"Structural neural plasticity evoked by rapid-acting antidepressant interventions","volume":"26","author":"Liao","year":"2025","journal-title":"Nat Rev Neurosci"},{"issue":"16","key":"10.1016\/j.genhosppsych.2025.07.001_bb0215","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"issue":"7966","key":"10.1016\/j.genhosppsych.2025.07.001_bb0220","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41586-023-06204-3","article-title":"Psychedelics reopen the social reward learning critical period","volume":"618","author":"Nardou","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0225","article-title":"Psychedelics and other Psychoplastogens for treating mental illness","volume":"12","author":"Vargas","year":"2021","journal-title":"Front Psych"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0230","series-title":"Behavioral neurobiology of psychedelic drugs","volume":"vol. 36","year":"2018"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.07.001_bb0235","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1073\/pnas.95.2.735","article-title":"5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites","volume":"95","author":"Jakab","year":"1998","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.genhosppsych.2025.07.001_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-08813-6","article-title":"Psilocybin\u2019s lasting action requires pyramidal cell types and 5-HT2A receptors","author":"Shao","year":"2025","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.genhosppsych.2025.07.001_bb0245","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","article-title":"Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor","volume":"182","author":"Kim","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.07.001_bb0250","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2016.12.033","article-title":"Crystal structure of an LSD-bound human serotonin receptor","volume":"168","author":"Wacker","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.07.001_bb0255","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1038\/s41467-025-57956-7","article-title":"The structural diversity of psychedelic drug actions revealed","volume":"16","author":"Gumpper","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.07.001_bb0260","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","article-title":"Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential","volume":"14","author":"Wallach","year":"2023","journal-title":"Nat Commun"},{"issue":"16","key":"10.1016\/j.genhosppsych.2025.07.001_bb0265","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2416106122","article-title":"Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential","volume":"122","author":"Tuck","year":"2025","journal-title":"Proc Natl Acad Sci"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834325001379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834325001379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:37:56Z","timestamp":1757335076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834325001379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":53,"alternative-id":["S0163834325001379"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2025.07.001","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should we skip the trip? Clinical implications of psychedelic-associated subjective effects and the potential role of non-hallucinogenic alternatives","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2025.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}